Rocuronium Bromide Injection, Solution
Product Images NDC 0409-3189

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 0409-3189). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rocuronium-spl-carton-100-mg (Rocuronium Spl Carton 100 mg)

Rocuronium-spl-carton-100-mg (Rocuronium Spl Carton 100 mg)
This is a description of a medical product called Rocuronium Bromide Injection. It is a sterile and nonpyrogenic solution used for intravenous use. Each milliliter of the solution contains 10 mg of rocuronium bromide and 2 mg of sodium acetate, adjusted to isotonicity and a pH of 4. It is important to note that this solution is a paralyzing agent and can cause respiratory arrest, so facilities must have artificial respiration capabilities available. The product should be stored under refrigeration between 2 to 8°C (36 to 46°F) and should not be frozen. Once removed from refrigeration, it can be stored at room temperature (25°C/77°F) for up to 60 days. Opened vials should be used within 30 days. The packaging of this product is not made with natural rubber latex. It is distributed by Hospira, Inc. and made in India. The product is sold in 100 mg/10 mL vials, with 10 vials in a package. The product is for intravenous use only and is available by prescription only.*
FDA Label Image

Rocuronium-spl-carton-50-mg (Rocuronium Spl Carton 50 mg)

Rocuronium-spl-carton-50-mg (Rocuronium Spl Carton 50 mg)
This text appears to be a description of a medication called Rocuronium Bromide Injection. It is a sterile, nonpyrogenic solution that is used as a paralyzing agent during medical procedures. The usual dosage is specified in the package insert. Each mL of the solution contains 10 mg of rocuronium bromide and 2 mg of sodium acetate. The pH of the solution is adjusted to 4 using acetic acid and/or sodium hydroxide. The text also warns that the medication can cause respiratory arrest, so facilities for artificial respiration should be immediately available. It should be stored under refrigeration and not frozen. Once removed from refrigeration, it should be used within 60 days. Once opened, vials should be used within 30 days. The packaging does not contain natural rubber latex. The product is made in India and distributed by Hospira, Inc. in the USA. The medication is for intravenous use only. The NDC code for this product is 0409-3189-10. The product comes in 10 x 5 mL multiple dose vials.*
FDA Label Image

Rocuronium-spl-fig-1 (Rocuronium Spl Fig 1)

FDA Label Image

Rocuronium-spl-fig-2 (Rocuronium Spl Fig 2)

FDA Label Image

Rocuronium-spl-fig-3 (Rocuronium Spl Fig 3)

FDA Label Image

Rocuronium-spl-fig-4 (Rocuronium Spl Fig 4)

FDA Label Image

Rocuronium-spl-structure (Rocuronium Spl Structure)

FDA Label Image

Rocuronium-spl-vial-100-mg (Rocuronium Spl Vial 100 mg)

FDA Label Image

Rocuronium-spl-vial-50-mg (Rocuronium Spl Vial 50 mg)

Rocuronium-spl-vial-50-mg (Rocuronium Spl Vial 50 mg)
This text provides information about a medication called Rocuronium Bromide Injection. It is a paralyzing agent that is intended for intravenous use only. The medication comes in a 5 mL multiple dose vial, with a concentration of 50 mg/5 mL (10 mg/mL). It is important to note that this medication can cause respiratory arrest, so facilities must have artificial respiration capabilities readily available. The medication should be stored in a refrigerator between 2 to 8°C (36 to 46°F) and should not be frozen. Once removed from the refrigerator, it should be used within 60 days if stored at room temperature (25°C/77°F) and within 30 days for opened vials. The product packaging does not contain natural rubber latex. The medication is distributed by Hospira, Inc. located in Lake Forest, IL, USA.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.